Century Therapeutics, Inc.
As of Oct 22, 2026, Century Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 24, 2026). It closed at $1.58, 46.3% below its 52-week high and below its 200-day average, which is rising.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IPSC early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IPSC among Biotechnology17th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …17 | IPSC | Stage 4 · wk 5 | 98 | −10.2% |
Century Therapeutics: quick answers
What stage is Century Therapeutics in?
As of Oct 22, 2026, Century Therapeutics (IPSC) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 24, 2026 and is in week 5. What the four stages mean
Is Century Therapeutics in an uptrend?
No. Century Therapeutics is in a Stage 4 downtrend. It trades 25.0% below its 200-day average, which is rising.
How far is Century Therapeutics from its 52-week high?
Century Therapeutics closed at $1.58 on Oct 22, 2026, 46.3% below its 52-week high of $2.94. Its 52-week low is $0.47.
How has Century Therapeutics performed over the past year?
As of Oct 22, 2026, Century Therapeutics is up 179.6% over the past year and up 58.8% so far in 2026.
Which sector and industry is Century Therapeutics in?
Century Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.